PIEZO1 and type 2 diabetes mellitus: Thus, pharmacological agents that promote the trafficking of PIEZO1 into the plasma membrane (perhaps targeting the residues that mediate the metabolic regulation) may represent a potential therapeutic means of restoring β-cell function in T2D.